Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Advanced Solid Tumor Cancer: early-phase trial registry

2 of 2 indexed Advanced Solid Tumor Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Advanced Solid Tumor Cancer: 2 US clinical trials tracked, 2 recruiting.

Advanced Solid Tumor Cancer is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Immunolight, running 1 of these trials.

Enrollment posture brief

Registry condition advanced-solid-tumor-cancer

OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Advanced Solid Tumor Can (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Advanced Solid Tumor Cancer

Advanced Solid Tumor Cancer lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Advanced Solid Tumor Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Advanced Solid Tumor Cancer is recruiting above its size-band peers.

    2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Top Sponsors

Immunolight 1 trials

Named interventions

Most-linked intervention names on Advanced Solid Tumor Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

X-PACT Combination
1 trials
Programmed Cell Death-1 (PD-1) Inhibitor Drug
1 trials
Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) Drug
1 trials
ABBV-CLS-484 Drug
1 trials

US sites by state

Facility locations filed on Advanced Solid Tumor Cancer trials. A trial with sites in several states counts in each.

North Carolina 2 trials
Texas 1 trials
South Carolina 1 trials
Rhode Island 1 trials
Pennsylvania 1 trials
New York 1 trials
Michigan 1 trials
Maryland 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Advanced Solid Tumor Cancer page

2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Advanced Solid Tumor Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Immunolight sponsors the most Advanced Solid Tumor Cancer trials on record, review their full trial history before evaluating a specific study. See Immunolight's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Solid Tumor Cancer condition card totals 2 registered trials; most-linked intervention X-PACT; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.